UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Therapeutics Corp (UTHR) is not a strong buy at the moment for a beginner, long-term investor. While the company has strong financial growth and positive analyst sentiment, the lack of immediate trading signals, insider selling, and a neutral technical setup suggest waiting for a better entry point. The stock may face short-term downside pressure, and the investor's impatience and unwillingness to wait for optimal entry points make this a less favorable buy right now.
The stock's technical indicators are mixed. The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 54.342, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 520.811, and resistance is at 545.195. The pre-market price of 539.98 is near resistance, suggesting limited upside in the short term.
Strong financial performance with revenue up 7.38% YoY, net income up 20.91% YoY, and EPS up 23.99% YoY in Q4
Positive analyst sentiment with multiple price target increases and a focus on upcoming catalysts, including clinical trial data for idiopathic pulmonary fibrosis and pulmonary arterial hypertension.
Bullish moving averages indicate long-term upward momentum.
Insiders are selling, with a 126.60% increase in selling activity over the last month.
The stock has an 80% chance of declining in the short term (-0.59% next day, -1.22% next week, -2.11% next month).
No recent news or congress trading data to provide additional positive sentiment.
In Q4 2025, United Therapeutics reported strong growth: Revenue increased by 7.38% YoY to $790.2M, net income rose by 20.91% YoY to $364.3M, and EPS grew by 23.99% YoY to 7.7. However, gross margin dropped slightly by -3.10% YoY to 86.91%.
Analysts have a positive outlook on UTHR, with multiple price target increases ranging from $486 to $705. Key drivers include strong performance in the pulmonary hypertension market, promising clinical trial data, and a solid product pipeline. However, some analysts maintain a neutral 'Equal Weight' rating, reflecting mixed sentiment on near-term performance.
